

FORM 7
MONTHLY PROGRESS REPORT

Name of Listed Issuer: **Nass Valley Gateway Ltd. (the “Issuer” or “Nass Valley”)**.

Trading Symbol: **NVG**

Number of Outstanding Listed Securities: **312,679,477 common shares**

Date: **May 3, 2019**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term “Issuer” includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

- 1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Company was inactive disclose this fact.

Nass Valley Gateway Ltd. (the “Company” or “Nass Valley”), common shares are listed for trading on the CSE under the symbol “NVG” and are co-listed on the “open market” of the Frankfurt Stock Exchange, trading under the symbol “3NVN”.

- 2. Provide a general overview and discussion of the activities of management.

The Company announced on April 15, 2019 that at its Board of Directors (“BoD”) meeting held on April 10, 2019 the BoD has confirmed its new CEO,

Mr. John Peter Affenita as President and CEO of the Company. The Company also established a Corporate Governance & Environment Committee consisting of three initial members which will be nominated in and appointed during its next BoD meeting.

The Nass Valley's BoD granted stock options to its Directors, Officers, Committee Members and Consultants of the Company including its subsidiaries, to purchase up to an aggregate of 1,555,000 common shares of the Company. The stock options will be exercisable at a price of \$0.18 per share with an expiring date on April 10, 2022.

3. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

NONE

4. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

As the CSE approved the terms of the Company's acquisition, Nass Valley Gateway will now operate through two wholly owned subsidiaries:

- 1. Advanced Bioceuticals Limited ("ABL"), incorporated under the Laws of New Jersey; and**
- 2. Pro-Thotics Technology Inc. ("PTI"), a New York corporation with more than 25 year established business.**

With PTI the Company will continue to focus on expanding the sale of Durable Medical Equipment ("DME-Products" or "PTI-Business") and increasing its database of more than 200,000 patients with service of providing relief from pain and medical issues via its DME-Products; and

Through its subsidiary ABL the Nass Valley is determined to expand upon this pain relief concept and to commence the sale of Cannabidiol (CBD) with zero THC content for internal use including CBD infused skin, bath, and body care products.

5. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

NONE

6. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how

the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

There were no acquisitions or dispositions by the Issuer in addition to the acquisition referred to under sections 2.

As previously stated, all considerations for the Company's completed acquisition which were subject to the approval were approved by the CSE and were executed on an arms-length relationship as part of the approval.

7. Describe the acquisition of new customers or loss of customers.

Nass Valley is confident that it has not lost any of its PTI-Business as described in section 4. and is also confident that it will replace those potential customers of its ABL-Business which the Company may have lost to existing competitors due to the prolonged approval process of its fundamental acquisition.

8. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

NONE

9. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None.

10. Report on any labour disputes and resolutions of those disputes if applicable.

None.

11. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

NONE

12. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

The Issuer has no debts outstanding and with its present corporate structure will have sufficient working capital to remain in good standing with all regulatory authorities.

14. Provide details of any securities issued and options or warrants granted

Security	Number Issued	Details of Issuance	Use of Proceeds
Common shares	536,000	The exercise of 280,000 stock options and 256,000 share purchase warrants	CAD 53,600
Options	None		N/A
Warrants	None		N/A

15. Provide details of any loans to or by Related Persons.

The Company did not receive any loans during the month of April 2019 and has no loans outstanding either to Related or Unrelated Persons.

16. Provide details of any changes in directors, officers or committee members.

On April 26, 2019 Dr. Samuel Alawieh submitted his resignation as Director and COO of the Company and its subsidiary Advanced Bioceticals Limited (“ABL”) for personal reasons. After discussion by the BoD, the Company accepted Dr. Alawieh’s resignation effective as of April 26, 2019 and will announce Dr. Alawieh’s replacement via a News Release very shortly.

During its board meeting held on April 26, 2019 the Chairman informed the BoD that Mr. Milo Filgas, a director and member of the Company’s Audit Committee, indicated that he intends to resign from the Company’s board and its audit committee subsequently to the company electing his replacement. During above BoD meeting, Mr. Darren Palestine, a graduate of the University of Florida with a Bachelor degree in marketing and Master’s degree in International Business was nominated as the new board member replacing Mr. Filgas, conditional of receiving the acceptance of Mr. Palestine’s Personal Information Form (“PIF”) by the CSE.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.

Nass Valley has historically relied upon equity financings to satisfy its capital requirements and will continue to depend upon equity funding to finance its activities for its growth. Although management is convinced that through the recent acquisition a positive cash flow will result for Nass Valley, the Company will still need additional capital to finance its planned marketing of its CBD products as soon as possible. Such capital will have to be partly originated from the exercise of outstanding stock options, warrants and also from the cash flow derived through the acquisition including the completion of measured equity financings or convertible debentures.

Nass Valley has presently operating income from its operations but will most likely raise additional funds in order to meet its rapid development objectives. Even though the Company has been successful in the past in financing its activities through the sale of securities and loans from insiders, there is no assurance that additional funding will be available to it for future development of its additional acquisitions. The Company's ability to arrange additional financing in the future will depend, in part, on the prevailing capital market conditions and success in its proposed projects.

There can be no assurance that continual fluctuations in the Company's share prices will not occur or that such fluctuations will not affect the ability of the Company to raise additional equity funding, and if at all, can be achieved via financial instruments avoiding significant additional dilution to its existing shareholders. Any quoted market for the common shares will be subject to market trends generally, notwithstanding any potential success of the Company in creating revenue, cash flows or earnings.

Although the Company believes that its subsidiaries' operations are in material compliance with current applicable regulations, no assurance can be given that a future change of laws will not result in a curtailment of production or a material adverse effect on the Company's business, financial condition, results of operations and prospects under development.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: **May 3, 2019.**

John Affenita
Name of Director or Senior
Officer

"John Affenita"
Signature
President & CEO
Official Capacity

	For Month Ended April 30, 2019	Date of Report YY/MM/D 19/05/3
Issuer Address 170-422 Richards Street		
City/Province/Postal Code Vancouver, B.C. V6B 2Z4	Issuer Fax No. (604) 568-9844	Issuer Telephone No. (516) 680-0433
Contact Name John Affenita	Contact Position President & CEO	Contact Telephone No. Direct (516) 680-0433
Contact Email Address info@nassvalleygateway.com	Web Site Address www.nassvalleygateway.com	